Subscribe to RSS
DOI: 10.1055/s-0043-107807
Neue adjuvante Therapien beim okulären Melanom
Novel Adjuvant Therapy for Ocular MelanomaPublication History
eingereicht 25 January 2017
akzeptiert 27 March 2017
Publication Date:
15 May 2017 (online)
![](https://www.thieme-connect.de/media/klimo/201705/lookinside/thumbnails/10-1055-s-0043-107807_kl1738-1.jpg)
Zusammenfassung
Hintergrund Das maligne Melanom ist der häufigste und bösartigste Tumor des Auges im Erwachsenenalter. Trotz erfolgreicher Behandlung des Primärtumors ist eine wirksame Therapie des metastasierenden konjunktivalen und uvealen Melanoms derzeit nicht bekannt. Die melanomassoziierte Lymphangiogenese sowie die Immunzellinfiltration sind wichtige Metastasierungsmechanismen und bieten potenzielle Ansatzpunkte, um eine neue adjuvante Therapie beim okulären Melanom zu etablieren.
Projektbeschreibung Die vorliegende Arbeit gibt einen kompakten Überblick über den aktuellen Wissensstand von Klinik und Forschung zum Thema der tumorassoziierten Lymphangiogenese und deren medikamentöser Hemmung sowie der Aktivierung des melanomassoziierten Immunzellinfiltrats mittels passiver oder aktiver Immuntherapie beim Melanom am Auge. Insbesondere werden die Forschungsansätze und wichtigsten Resultate unserer bisherigen Arbeiten sowie unserer aktuellen translationalen Forschung zu diesem Thema im Teilprojekt 4 „Melanom am Auge“ der Forschergruppe FOR 2240 „(Lymph)Angiogenesis and Cellular Immunity in Inflammatory Diseases of the Eye“ zusammengefasst.
Schlussfolgerungen Die Hemmung der inflammatorischen Lymphangiogenese und die Modulation von Immunantworten könnten einen vielversprechenden Ansatz beim malignen Melanom am Auge darstellen, um das Überleben dieser Patienten zu verlängern.
Abstract
Background Malignant melanoma is the most common cancer of the eye in adults that originates either in the intra-ocular uveal tract or extra-ocular conjunctiva. Although the primary tumor can be treated successfully, no effective therapy for both metastatic conjunctival and uveal melanoma currently exits. Tumor-associated lymphangiogenesis and immune cell infiltration play a pivotal role in the development and therapeutic targeting of metastases.
Project description Here, we provide an overview of current translational research on lymphangiogenesis and its therapeutic inhibition as well as modulation of immune cell infiltration by passive and active immunotherapy in melanoma of the eye. Specifically, our previous and ongoing work on lymphangiogenesis and immune cells in ocular melanoma within the clinical research unit FOR 2240 “(Lymph)Angiogenesis and Cellular Immunity in Inflammatory Diseases of the Eye” is summarized.
Conclusions Translational research on the modulation of tumor-associated lymphangiogenesis and immune cell infiltration could provide novel targets for adjuvant therapy in melanoma of the eye.
-
Literatur
- 1 Kaliki S, Shields CL. Uveal melanoma: relatively rare but deadly cancer. Eye 2017; 31: 241-277
- 2 Bornfeld N, Bechrakis NE. Perspectives in ocular oncology. Klin Monatsbl Augenheilkd 2010; 227: 529
- 3 Augsburger JJ, Corrêa ZM, Shaikh AH. Effectiveness of treatments for metastatic uveal melanoma. Am J Ophthalmol 2009; 148: 119-127
- 4 Shildkrot Y, Wilson MW. Conjunctival melanoma: pitfalls and dilemmas in management. Curr Opin Ophthalmol 2010; 21: 380-386
- 5 Heindl LM, Lotter M, Strnad V. et al. Hochdosisbrachytherapie des malignen Aderhaut- und Ziliarkörpermelanoms mit 106 Ruthenium. Eine klinisch-pathologische Studie. Ophthalmologe 2007; 104: 149-157
- 6 Blum ES, Yang J, Komatsubara KM. et al. Clinical management of uveal and conjunctival melanoma. Oncology 2016; 30: 29-32 34–43, 48
- 7 Kujala E, Kivelä T. Tumor, node, metastasis classification of malignant ciliary body and choroidal melanoma evaluation of the 6th edition and future directions. Ophthalmology 2005; 112: 1135-1144
- 8 Dithmar S, Diaz CE, Grossniklaus HE. Intraocular melanoma spread to regional lymph nodes: report of two cases. Retina 2000; 20: 76-79
- 9 Patel SP. Latest developments in the biology and management of uveal melanoma. Curr Oncol Rep 2013; 15: 509-516
- 10 Leyvraz S, Keilholz U. Ocular melanoma: whatʼs new?. Curr Opin Oncol 2012; 24: 162-169
- 11 Streilein JW. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol 2003; 3: 879-889
- 12 Niederkorn JY. See no evil, hear no evil, do no evil: the lessons of immune privilege. Nat Immunol 2006; 7: 354-359
- 13 Heindl LM, Schrödl F, Lütjen-Drecoll E. et al. Ciliary body lymphangiogenesis. Ophthalmology 2013; 120: e41-e42
- 14 Schrödl F, Kaser-Eichberger A, Trost A. et al. Lymphatic markers in the adult human choroid. Invest Ophthalmol Vis Sci 2015; 56: 7406-7416
- 15 Kaser-Eichberger A, Schrödl F, Trost A. et al. Topography of lymphatic markers in human iris and ciliary body. Invest Ophthalmol Vis Sci 2015; 56: 4943-4953
- 16 Schlereth SL, Neuser B, Herwig MC. et al. Absence of lymphatic vessels in the developing human sclera. Exp Eye Res 2014; 125: 203-209
- 17 Zimmermann P, Dietrich T, Bock F. et al. Tumour-associated lymphangiogenesis in conjunctival malignant melanoma. Br J Ophthalmol 2009; 93: 1529-1534
- 18 Heindl LM, Hofmann TN, Knorr HL. et al. Intraocular lymphangiogenesis in malignant melanomas of the ciliary body with extraocular extension. Invest Ophthalmol Vis Sci 2009; 50: 1988-1995
- 19 Heindl LM, Hofmann TN, Adler W. et al. Intraocular tumor-associated lymphangiogenesis a novel prognostic factor for ciliary body melanomas with extraocular extension?. Ophthalmology 2010; 117: 334-342
- 20 Heindl LM, Hofmann TN, Schrödl F. et al. Intraocular lymphatics in ciliary body melanomas with extraocular extension: functional for lymphatic spread?. Arch Ophthalmol 2010; 128: 1001-1008
- 21 Heindl LM, Hofmann-Rummelt C, Adler W. et al. Tumor-associated lymphangiogenesis in the development of conjunctival melanoma. Invest Ophthalmol Vis Sci 2011; 52: 7074-7083
- 22 Heindl LM, Hofmann-Rummelt C, Adler W. et al. Prognostic significance of tumor-associated lymphangiogenesis in malignant melanomas of the conjunctiva. Ophthalmology 2011; 118: 2351-2360
- 23 Koch KR, Refaian N, Hos D. et al. Autocrine impact of VEGF-A on uveal melanoma cells. Invest Ophthalmol Vis Sci 2014; 55: 2697-2704
- 24 Refaian N, Schlereth SL, Koch KR. et al. Comparing the hem- and lymphangiogenic profile of conjunctival and uveal melanoma cell lines. Invest Ophthalmol Vis Sci 2015; 56: 5691-5697
- 25 Schlereth SL, Iden S, Mescher M. et al. A novel model of metastatic conjunctival melanoma in immune-competent mice. Invest Ophthalmol Vis Sci 2015; 56: 5965-5973
- 26 Schlereth SL, Neuser B, Caramoy A. et al. Enrichment of lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1)-positive macrophages around blood vessels in the normal human sclera. Invest Ophthalmol Vis Sci 2014; 55: 865-872
- 27 Schlereth SL, Kremers S, Schrödl F. et al. Characterization of antigen-presenting macrophages and dendritic cells in the healthy human sclera. Invest Ophthalmol Vis Sci 2016; 57: 4878-4885
- 28 Grajewski RS, Bosch JJ, Bruns H. et al. The Trojan horse tale revisited: an eye on metastatic spread of carcinoma cells. Cancer Immunol Res 2016; 4: 92-94
- 29 Bosch JJ, Thompson JA, Srivastava MK. et al. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells. Cancer Res 2007; 67: 4499-4506
- 30 Bosch JJ, Iheagwara UK, Reid S. et al. Uveal melanoma cell-based vaccines express MHC II molecules that traffic via the endocytic and secretory pathways and activate CD8+ cytotoxic, tumor-specific T cells. Cancer Immunol Immunother 2010; 59: 103-112
- 31 Franklin C, Livingstone E, Roesch A. et al. Immunotherapy in melanoma: Recent advances and future directions. Eur J Surg Oncol 2017; 43: 604-611
- 32 Griewank KG, Westekemper H, Murali R. et al. Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas. Clin Cancer Res 2013; 19: 3143-3152
- 33 Damato B, Coupland SE. Management of conjunctival melanoma. Expert Rev Anticancer Ther 2009; 9: 1227-1239
- 34 Heindl LM, Cursiefen C. Bindehautmelanom – eine Systemerkrankung. Ophthalmologe 2015; 112: 890-891
- 35 Bock F, Maruyama K, Regenfuss B. et al. Novel anti(lymph)angiogenic treatment strategies for corneal and ocular surface diseases. Prog Retin Eye Res 2013; 34: 89-124
- 36 Field MG, Harbour JW. Recent developments in prognostic and predictive testing in uveal melanoma. Curr Opin Ophthalmol 2014; 25: 234-239
- 37 Zimmer L, Vaubel J, Mohr P. et al. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma. PLoS One 2015; 10: e0118564
- 38 Algazi AP, Tsai KK, Shoushtari AN. et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer 2016; 122: 3344-3353
- 39 Bosch JJ. Immunotherapy of uveal melanoma. Dev Ophthalmol 2012; 49: 137-149
- 40 Tschentscher F, Hüsing J, Hölter T. et al. Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res 2003; 63: 2578-2584
- 41 Onken MD, Ehlers JP, Worley LA. et al. Functional gene expression analysis uncovers phenotypic switch in aggressive uveal melanomas. Cancer Res 2006; 66: 4602-4609
- 42 Schuler-Thurner B, Bartz-Schmidt KU, Bornfeld N. et al. Immunotherapy of uveal melanoma: vaccination against cancer. Multicenter adjuvant phase 3 vaccination study using dendritic cells laden with tumor RNA for large newly diagnosed uveal melanoma. Ophthalmologe 2015; 112: 1017-1021
- 43 Heindl LM, Koch KR, Schlaak M. et al. Adjuvante Therapie und interdisziplinäre Nachsorge des Bindehautmelanoms. Ophthalmologe 2015; 112: 907-911